JPMorgan upgraded Precigen (PGEN) to Neutral from Underweight without a price target following the FDA’s approval of Papzimeos. The firm cites the removal of Precigen’s “major regulatory overhang” and its revenue potential for the upgrade. However, the adoption of Papzimeos will take time to materialize, the analyst tells investors in a research note. JPMorgan believes that with limited cash on the balance sheet to support the launch, further dilution post approval is “likely inevitable” for Precigen.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGEN:
- Precigen jumps 32% to $2.44 after FDA approval of Papzimeos
- FDA approves Precigen immunotherapy for respiratory papillomatosis
- Precigen trading halted, news pending
- Precigen’s Transformative Potential: Buy Rating Backed by Imminent FDA Decision and Strong Financial Outlook
- Precigen, Inc. Reports Q2 2025 Earnings and Strategic Focus